BMI View: Moldova started the year on a shaky footing, with a political crisis and the shadow of H212′s recession hanging over the government. Now that a sense of stability is returning, politicians can focus on mapping out Moldova’s future within the EU – which would have widespread implications for the pharmaceutical and healthcare markets. Concerns about the quality of drugs produced in the country shape the market. This quarter has seen drug withdrawals and domestic firms keen to meet GMP standards, but we forecast that local pharmaceutical players will play a minor role in drug production over the course …
Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=118177.
Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/moldova-pharmaceuticals-and-healthcare-report-q4-2013-market-report.html.
No comments:
Post a Comment